Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Stock Has Consensus Price Target of $17.17 According to Analysts

Key Points

• Analysts’ consensus is “Moderate Buy” among 10 firms, with an average one-year price target of $17.17. Seven rate EPRX Buy and one Strong Buy, while two rate it Hold or Sell.
• Eupraxia reported a third-quarter loss of $0.23 per share, narrower than analysts’ expected $0.26 loss, but the company remains unprofitable.
• The company established a $125 million at-the-market offering program, giving it a way to raise capital over time but potentially diluting existing shareholders if shares are sold.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $17.17.

A number of equities research analysts have recently commented on EPRX shares. Royal Bank Of Canada started coverage on Eupraxia Pharmaceuticals in a research report on Monday. They issued an "outperform" rating and a $14.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $11.00 target price on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 1st. Wedbush assumed coverage on Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. They set an "outperform" rating and a $17.00 target price on the stock. Wall Street Zen lowered Eupraxia Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Sunday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, October 15th.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Affinity Asset Advisors LLC grew its holdings in Eupraxia Pharmaceuticals by 429.7% in the first quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company's stock valued at $11,504,000 after purchasing an additional 1,289,005 shares during the period. Jupiter Topco LLC purchased a new position in Eupraxia Pharmaceuticals during the second quarter worth approximately $6,851,000. Seven Fleet Capital Management LP purchased a new position in Eupraxia Pharmaceuticals during the first quarter worth approximately $5,137,000. Redmile Group LLC purchased a new position in Eupraxia Pharmaceuticals during the first quarter worth approximately $5,068,000. Finally, Rubric Capital Management LP purchased a new position in Eupraxia Pharmaceuticals during the first quarter worth approximately $5,004,000.

Eupraxia Pharmaceuticals Stock Up 2.8%

EPRX stock opened at $7.63 on Wednesday. The company has a 50 day moving average price of $7.58 and a two-hundred day moving average price of $7.25. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.00 and a current ratio of 16.00. The stock has a market capitalization of $513.04 million, a P/E ratio of -7.48 and a beta of 1.04. Eupraxia Pharmaceuticals has a one year low of $5.63 and a one year high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.03. As a group, sell-side analysts expect that Eupraxia Pharmaceuticals will post -0.90 EPS for the current year.

Eupraxia Pharmaceuticals News Roundup

Here are the key news stories impacting Eupraxia Pharmaceuticals this week:

• Positive Sentiment: Eupraxia reported a third-quarter 2026 loss of $0.23 per share, narrower than the $0.26 loss analysts expected. The earnings beat may be encouraging, although the company remains loss-making. Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results
• Positive Sentiment: RBC Capital initiated coverage with an Outperform rating and a $14 price target, while flagging the stock as speculative risk. The rating signals analyst optimism, balanced by the high-risk designation. RBC Capital Starts Eupraxia Pharmaceuticals at Outperform
• Negative Sentiment: The company established a $125 million at-the-market offering program, allowing it to sell shares over time. The financing provides access to capital but could dilute existing shareholders if shares are issued. Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc. is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability. Eupraxia's lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.